Clinical trials: Major Depressive Disorder
Major Depressive Disorder
Reward Function and Therapy for Late-Life Depression
The goal of this study is to learn about changes in the brain that occur during Engage, a psychotherapy for depression in older adults, and how they may differ from changes that occur during supportive therapy.
- Trial name
- NCT03688139
- Testing
- Engage Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder
Study Of 323U66 SR In Major Depressive Disorder
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
- Trial name
- NCT00135512
- Testing
- bupropion hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 234 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Anxiety Disorder
Tapering Off Antidepressants
The purpose of this study is to compare two ways to stop taking an antidepressant medication and determine whether a faster or slower taper is better tolerated.
- Conditions
- Major Depressive Disorder, Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder
- Trial name
- NCT02661828
- Testing
- Two-Week Antidepressant Taper Regimen, One-Week Antidepressant Taper Regimen
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Depression, Suicide
Ketamine for Depression and Suicide Risk
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S.
- Trial name
- Ketamine (NCT02094898)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder
HypErthermia as an Additional Treatment for the Biology and Experience of Depression
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or…
- Trial name
- HEATBED (NCT05041361)
- Testing
- Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Generalized Anxiety Disorder
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
The primary objective of the study is to determine whether quetiapine extended-release in combination with cognitive behavioral therapy (CBT) is more effective than CBT plus placebo in treating depressive and anxiety symptoms in…
- Trial name
- NCT01971203
- Testing
- seroquel xr, CBT
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Major Depressive Disorder
A Study of Ketamine in Patients With Treatment-resistant Depression
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
- Trial name
- NCT01627782
- Testing
- Ketamine
- Where
- 13 sites in United States
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Relapse
Ketamine for Relapse Prevention in Recurrent Depressive Disorder
Randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam for depression relapse prevention in persons at high risk.
- Conditions
- Depression, Relapse, Recurrent Depressive Disorder, Major Depressive Disorder
- Trial name
- KINDRED (NCT02661061)
- Testing
- Ketamine, Midazolam
- Where
- Ireland
- Volunteers
- 9 people
- Sponsor
- St Patrick's Hospital, Ireland
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Major Depressive Disorder
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)
The primary objective of this study are to evaluate the synergistic effect of a combination product, consisting of drug BCI-024 (buspirone) and drug BCI-049 (melatonin), in reducing symptoms of depression in patients with Major…
- Trial name
- NCT00705003
- Testing
- BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD, BCI-024 (Buspirone)
- Where
- 9 sites in United States
- Volunteers
- 142 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
- Trial name
- NCT02586688
- Testing
- Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Neuronetics
Bipolar Disorder, Bipolar Depression
Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Mixed states in bipolar disorder have long been recognized. Over a century ago, it was argued that mixed states were the most common episodes in manic-depressive illness.
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- NCT00490542
- Testing
- ziprasidone (Geodon)
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Tufts Medical Center
Depression
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
This study will examine multiple carefully selected clinical and biological markers, using both existing state-of-the-art technologies as well as pioneering, innovative approaches.
- Trial name
- EMBARC (NCT01407094)
- Testing
- Sertraline, BupropionXL
- Where
- 4 sites in United States
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Infant, Newborn, Hypoxia, Brain
Preemie Hypothermia for Neonatal Encephalopathy
This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01793129
- Testing
- Hypothermia, Normothermic Control
- Where
- 18 sites in United States
- Volunteers
- 168 people
- Sponsor
- NICHD Neonatal Research Network
Major Depressive Disorder, Menopause
A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
HYPOTHESIS: Pregnenolone administration will be associated with greater reduction in depressive symptom severity than placebo in women with current mMDD.
- Conditions
- Major Depressive Disorder, Menopause, Perimenopause
- Trial name
- NCT03505905
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Texas Southwestern Medical Center